{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:31:40Z","timestamp":1782448300991,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.clml.2012.12.006","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T04:46:49Z","timestamp":1357793209000},"page":"307-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes"],"prefix":"10.1016","volume":"13","author":[{"given":"Wenli","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi-Kashani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop H.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.12.006_bib1","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with AML: a population based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.12.006_bib2","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.006_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.blre.2010.10.002","article-title":"Independent prognostic variables in acute myeloid leukaemia","volume":"25","author":"Smith","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2012.12.006_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-8722-3-17","article-title":"Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights","volume":"3","author":"Zhu","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2012.12.006_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/asheducation-2011.1.243","article-title":"Novel antibody-based therapies for acute lymphoblastic leukemia","volume":"2011","author":"Hoelzer","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2012.12.006_bib6","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.12.006_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2012.12.006_bib8","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.12.006_bib9","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.12.006_bib10","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.12.006_bib11","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2012-05-430918","article-title":"Brentuximab vedotin for relapsed or refractory CD30-positive hematologic malignancies: the German Hodgkin Study Group experience","volume":"120","author":"Rothe","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.006_bib12","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood.V81.12.3388.3388","article-title":"Biologic characteristics of acute leukemia after myelodysplastic syndrome","volume":"81","author":"Masuya","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.006_bib13","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/annonc\/mdh268","article-title":"CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature","volume":"15","author":"Bekkenk","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2012.12.006_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/10428190109058000","article-title":"t(2; 5) associated with a histiocytic-monocytic neoplasm","volume":"41","author":"Lemes","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.12.006_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.leu.2404491","article-title":"Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients","volume":"21","author":"Pileri","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2012.12.006_bib16","article-title":"CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis","author":"Fathi","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.12.006_bib17","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"134","article-title":"Acute myeloid leukemia, not otherwise specified","author":"Arber","year":"2008"},{"key":"10.1016\/j.clml.2012.12.006_bib18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.006_bib19","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.006_bib20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.006_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1309\/AJCPEI9XU8PYBCIO","article-title":"FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia","volume":"135","author":"Bains","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2012.12.006_bib22","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1309\/JT5BE2L1FGG8P8Y6","article-title":"Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia","volume":"126","author":"Lin","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2012.12.006_bib23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/modpathol.2009.59","article-title":"Application of COLD-PCR for improved detection of KRAS mutations in clinical samples","volume":"22","author":"Zuo","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2012.12.006_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/smim.1998.0156","article-title":"CD30: expression and function in health and disease","volume":"10","author":"Horie","year":"1998","journal-title":"Semin Immunol"},{"key":"10.1016\/j.clml.2012.12.006_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/978-0-387-89520-8_12","article-title":"Targeting CD30\/CD30L in oncology and autoimmune and inflammatory diseases","volume":"647","author":"Oflazoglu","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clml.2012.12.006_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/clim.1998.4636","article-title":"CD30 in normal and neoplastic cells","volume":"90","author":"Chiarle","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clml.2012.12.006_bib27","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3109\/10428194.2010.550072","article-title":"Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms","volume":"52","author":"Valent","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.12.006_bib28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/modpathol.2010.224","article-title":"Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis","volume":"24","author":"Sotlar","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2012.12.006_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10428199909145702","article-title":"CD30 ligand (CD30L)-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cells proliferation","volume":"35","author":"Gattei","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.12.006_bib30","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1182\/blood.V89.6.2048","article-title":"CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin","volume":"89","author":"Gattei","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.006_bib31","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ajpath.2011.10.007","article-title":"Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma","volume":"180","author":"Watanabe","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2012.12.006_bib32","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/modpathol.3800419","article-title":"JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis","volume":"18","author":"Rassidakis","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2012.12.006_bib33","first-page":"CR359","article-title":"Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry","volume":"9","author":"Rezaei","year":"2003","journal-title":"Med Sci Monit"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:45Z","timestamp":1761870225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012002923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S2152265012002923"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.12.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}